LifeArc/MDUK – Muscular Dystrophy Translational Research Fund
Closing Date: 31/05/2022
Funding for translational research projects to advance the development of new treatments for people with Congenital Muscular Dystrophies (CMD).
Muscular Dystrophy UK (MDUK) and LifeArc are co-funding the Muscular Dystrophy Translational Research Fund to support projects with the potential to accelerate new treatments for Congenital Muscular Dystrophies (CMD).
CMDs are typically detected at birth or in the first few months of life and share a common muscle pathology. There are no current effective treatments for CMDs, which are caused by mutations in different genes and vary in severity of symptoms.
MDUK and LifeArc are seeking to encourage and support treatment-focused, milestone-driven medical research projects, which are already on the translational pathway, to develop effective, new treatments for CMD. Funding in the order of £300,000-£400,000 will be available to support projects over a maximum duration of three years.
Proposed projects should:
- Seek to develop a therapeutic intervention to address the need for more effective treatments for CMD
- Have a strong scientific rationale
- Be a target-driven, with milestones and a credible delivery plan
- Have a clearly set-out route to CMD patients.
Projects/activities eligible for support include:
- Developing candidate therapeutic entities (eg drug discovery)
- Pre-clinical testing of novel therapeutic entities in vitro or in vivo
- Pre-clinical validation for existing therapeutics repurposed for CMD
- Early-phase clinical trials (phase 1/2) of novel therapeutic entities
- Early-phase clinical trials of existing therapeutics repurposed for CMD.
Methods of treatment within scope include small molecules, peptides, antibodies, gene therapies (including antisense oligonucleotides), cellular therapies, and regenerative medicine.
It is hoped that projects will generate valuable outcomes that can secure follow-on funding (ie additional translational research funding or partnering with/licensing to industry) to support continued development and progression towards clinical trials.
Biotechnology and Biology
|Fund or call||Fund|